Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash & Current Investments (2017 - 2025)

Cue Biopharma's Cash & Current Investments history spans 9 years, with the latest figure at $18.7 million for Q3 2025.

  • For Q3 2025, Cash & Current Investments changed N/A year-over-year to $18.7 million; the TTM value through Sep 2025 reached $18.7 million, up 89.32%, while the annual FY2024 figure was $22.5 million, 53.98% down from the prior year.
  • Cash & Current Investments for Q3 2025 was $18.7 million at Cue Biopharma, up from $470000.0 in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $76.3 million in Q4 2022 and bottomed at $470000.0 in Q2 2025.
  • The 5-year median for Cash & Current Investments is $48.8 million (2023), against an average of $40.7 million.
  • The largest annual shift saw Cash & Current Investments skyrocketed 315.36% in 2024 before it tumbled 97.78% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $52.2 million in 2021, then soared by 46.12% to $76.3 million in 2022, then plummeted by 36.03% to $48.8 million in 2023, then plummeted by 53.98% to $22.5 million in 2024, then fell by 16.73% to $18.7 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Cash & Current Investments are $18.7 million (Q3 2025), $470000.0 (Q2 2025), and $912000.0 (Q1 2025).